- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Laura Topor Discusses Challenges of e-Prescribing Specialty Medications
Prescribers and pharmacies can encounter some unique challenges when specialty drugs are e-prescribed, but organizations like the National Council for Prescription Drug Programs are trying to make the process smoother, explained Laura Topor, president of Granada Health.
Prescribers and pharmacies can encounter some unique challenges when specialty drugs are e-prescribed, but organizations like the National Council for Prescription Drug Programs (NCPDP) are trying to make the process smoother, explained Laura Topor, president of Granada Health.
Transcript (slightly modified)
What are the challenges of e-prescribing specialty medications, and how can they be overcome?
I’ve spent a fair amount of time through NCPDP trying to improve the standard to support e-prescribing of specialty medications, and what we’ve found is there were a lot of elements on that intake or enrollment form that a specialty pharmacy has that weren’t included. They maybe would send the prescription and still be faxing the form in, so we’ve enhanced the standard, which will be available when the new regulations come out that allow us to use it, that will simplify that process. We added things like gestational age and hospice indicators and IV administration elements.
The other challenge is often because of where the product can be dispensed, and the prescriber doesn’t know that, so we’re trying to figure that piece out to make sure that the prescription gets to the right pharmacy. We’ve got some work to do there, but it’s… Who’s going to get that prior authorization? Is the right information moving? Is it going to a pharmacy; is it going to a hub? All of those components we’re trying to address in enhancing the e-prescribing transactions.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
